Theranostics Market by Product (Diagnostic imaging (PET, CT, MRI), Radiopharmaceuticals (Lu-177, Sm-153, Ra-223, I-131), Biomarker screening, Software), Application (Prostate Cancer, Bone metastasis), & Stakeholder Expectations - Global Forecast to 2028
The global theranostics market is projected to reach USD 4.3 billion by 2028 from USD 2.1 billion in 2023, at a CAGR of 15.5% from 2023 to 2028. Factors such as rising baby boomer population and advances in research and development of radiopharmceuticals are responsible for the increasing growth of this market. Increasing research and development activities, rising number of clinical trials, and government initiatives attributes to the growth of theranostics market.
“The radiopharmaceuticals segment held the largest share of the market in 2022.”
Based on product, the theranostics market is segmented into diagnostic imaging, radiopharmaceuticals, IVD/biomarker screening, and software and services. The radiopharmaceuticals segment held the largest market share in 2022. The large share of this segment can be attributed to the rising adoption of theranostics and increasing prevalence of chronic diseases such as cancer.
“The prostate cancer application segment is projected to register the highest CAGR of the theranostics market by application during the forecast period.”
Based on application, the theranostics market is segmented into prostate cancer, bone metastasis, other cancer, and other applications. The prostate cancer application segment is projected to register the highest CAGR of the theranostics market from 2023 to 2028. Factors such as rising number of cancer population and ongoing clinical trials to know the benefits of theranostics for other applications are driving the market growth.
“The market in the Asia Pacific region is expected to witness the highest growth during the forecast period.”
The theranostics market in the APAC region is expected to register the highest CAGR during the forecast period, primarily due to evolving healthcare infrastructure and increasing focus of major players in the region. The healthcare infrastructure in emerging economies, such as China and India is evolving at a rapid pace, leading to major investments by hospitals and other end users. These factors are anticipated to fuel the growth of theranostics market in this region.
A breakdown of the primary participants referred to for this report is provided below:
Research Coverage
This report studies the theranostics market based on product, application, end user, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their growth trends and forecasts the revenue of the market segments with respect to three main regions (and the respective countries in these regions).
Reasons to Buy the Report
The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall theranostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.
This report provides insights on the following pointers:
“The radiopharmaceuticals segment held the largest share of the market in 2022.”
Based on product, the theranostics market is segmented into diagnostic imaging, radiopharmaceuticals, IVD/biomarker screening, and software and services. The radiopharmaceuticals segment held the largest market share in 2022. The large share of this segment can be attributed to the rising adoption of theranostics and increasing prevalence of chronic diseases such as cancer.
“The prostate cancer application segment is projected to register the highest CAGR of the theranostics market by application during the forecast period.”
Based on application, the theranostics market is segmented into prostate cancer, bone metastasis, other cancer, and other applications. The prostate cancer application segment is projected to register the highest CAGR of the theranostics market from 2023 to 2028. Factors such as rising number of cancer population and ongoing clinical trials to know the benefits of theranostics for other applications are driving the market growth.
“The market in the Asia Pacific region is expected to witness the highest growth during the forecast period.”
The theranostics market in the APAC region is expected to register the highest CAGR during the forecast period, primarily due to evolving healthcare infrastructure and increasing focus of major players in the region. The healthcare infrastructure in emerging economies, such as China and India is evolving at a rapid pace, leading to major investments by hospitals and other end users. These factors are anticipated to fuel the growth of theranostics market in this region.
A breakdown of the primary participants referred to for this report is provided below:
- By Company Type: Tier 1–48%, Tier 2–36%, and Tier 3– 16%
- By Designation: Director-level–14%, C-level–10%, and Others–76%
- By Region: North America–40%, Europe–32%, Asia Pacific–20%, Rest of the World- 8%
Research Coverage
This report studies the theranostics market based on product, application, end user, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their growth trends and forecasts the revenue of the market segments with respect to three main regions (and the respective countries in these regions).
Reasons to Buy the Report
The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall theranostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.
This report provides insights on the following pointers:
- Analysis of key drivers (growing geriatric population and rising prevalence of associated diseases, rising use of radiophamrceuticals, rising focus on precision medicine), restraints (short life of radiopharmceuticals, unfavourable reimbursement scenario), opportunities (growth opportunities in emerging countries, advances in research and development of radiopharmceuticals), and challenges (hospital budget cuts and high equipment costs) influencing the growth of the theranostics market
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the theranostics market
- Market Development: Comprehensive information about lucrative markets–the report analyses the theranostics market across varied regions
- Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the theranostics market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Advanced Accelerator Applications (France), Bayer AG (Germany), GE Healthcare (US).
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 INCLUSIONS & EXCLUSIONS
1.4 MARKET SEGMENTATION
1.4.1 MARKETS COVERED
1.4.2 REGIONS COVERED
1.4.3 YEARS CONSIDERED
1.4.4 CURRENCY CONSIDERED
1.5 RESEARCH LIMITATIONS
1.6 STAKEHOLDERS
1.7 RECESSION IMPACT: THERANOSTICS MARKET
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN METHODOLOGY
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.1.2.1 Primary sources
2.1.2.2 Key industry insights
2.1.2.3 Breakdown of primaries
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 Approach 1: Company revenue estimation approach
FIGURE 5 COMPANY REVENUE ESTIMATION
FIGURE 6 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF BAYER AG
2.2.1.2 Approach 2: Patient population-based market estimation
FIGURE 7 BOTTOM-UP APPROACH: THERANOSTICS MARKET
2.2.1.3 Growth forecast
2.2.1.4 CAGR projections
FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 9 DATA TRIANGULATION METHODOLOGY
2.3.1 MARKET SHARE ESTIMATION
2.4 STUDY ASSUMPTIONS
2.4.1 MARKET ASSUMPTIONS
2.4.2 GROWTH RATE ASSUMPTIONS
2.5 RISK ASSESSMENT
TABLE 1 RISK ASSESSMENT: THERANOSTICS MARKET
2.6 IMPACT OF ECONOMIC RECESSION ON THERANOSTICS MARKET
3 EXECUTIVE SUMMARY
FIGURE 10 THERANOSTICS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
FIGURE 11 THERANOSTICS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
FIGURE 12 THERANOSTICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 13 REGIONAL SNAPSHOT OF THERANOSTICS MARKET
4 PREMIUM INSIGHTS
4.1 THERANOSTICS MARKET OVERVIEW
FIGURE 14 RISING PREVALENCE OF CANCER AND GROWING FOCUS ON PRECISION MEDICINE TO DRIVE MARKET
4.2 NORTH AMERICA: THERANOSTICS MARKET, BY PRODUCT (USD MILLION)
FIGURE 15 RADIOPHARMACEUTICALS TO COMMAND LARGEST MARKET SHARE IN NORTH AMERICAN THERANOSTICS MARKET DURING FORECAST PERIOD
4.3 EUROPE: THERANOSTICS MARKET, BY APPLICATION (USD MILLION)
FIGURE 16 PROSTATE CANCER TO REGISTER HIGHEST GROWTH RATE DURING STUDY PERIOD
4.4 ASIA PACIFIC: THERANOSTICS MARKET, BY END USER (USD MILLION)
FIGURE 17 HOSPITALS AND CANCER CARE CENTERS TO COMMAND LARGEST SHARE IN ASIA PACIFIC MARKET DURING FORECAST PERIOD
4.5 GEOGRAPHIC SNAPSHOT: THERANOSTICS MARKET
FIGURE 18 CHINA TO WITNESS HIGHEST GROWTH RATE DURING STUDY PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 19 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: THERANOSTICS MARKET
5.2.1 DRIVERS
5.2.1.1 Growing geriatric population and rising prevalence of target diseases
5.2.1.2 Increasing use of radiopharmaceuticals in neurological applications
5.2.1.3 Growing focus on precision medicine
5.2.2 RESTRAINTS
5.2.2.1 Short half-life of radiopharmaceuticals
TABLE 2 PHYSICAL HALF-LIFE OF RADIOPHARMACEUTICALS
5.2.2.2 Unfavorable healthcare reimbursement scenario
5.2.3 OPPORTUNITIES
5.2.3.1 Growth opportunities in emerging economies
5.2.3.2 Rising number of R&D programs for radiopharmaceuticals
5.2.4 CHALLENGES
5.2.4.1 Hospital budget cuts and high equipment costs
5.3 PRICING ANALYSIS
FIGURE 20 AVERAGE SELLING PRICE FOR RADIOPHARMACEUTICALS
TABLE 3 AVERAGE COST FOR THERANOSTICS TREATMENT, BY REGION
5.4 VALUE CHAIN ANALYSIS
FIGURE 21 VALUE CHAIN ANALYSIS: THERANOSTICS MARKET
5.5 ECOSYSTEM/MARKET MAP
5.6 SUPPLY CHAIN ANALYSIS
5.6.1 PROMINENT COMPANIES
5.6.2 SMALL & MEDIUM-SIZED ENTERPRISES
5.6.3 END USERS
FIGURE 22 SUPPLY CHAIN ANALYSIS: THERANOSTICS MARKET
5.7 PORTER’S FIVE FORCES ANALYSIS
TABLE 4 PORTER’S FIVE FORCES ANALYSIS: THERANOSTICS MARKET
5.7.1 INTENSITY OF COMPETITIVE RIVALRY
5.7.2 BARGAINING POWER OF SUPPLIERS
5.7.3 BARGAINING POWER OF BUYERS
5.7.4 THREAT OF SUBSTITUTES
5.7.5 THREAT OF NEW ENTRANTS
5.8 REGULATORY LANDSCAPE
5.8.1 NORTH AMERICA
5.8.1.1 US
5.8.1.2 Canada
5.8.2 EUROPE
5.8.3 ASIA PACIFIC
5.8.3.1 Australia
5.8.3.2 India
5.8.3.3 China
5.8.4 REST OF THE WORLD
5.8.4.1 Turkey
5.8.4.2 UAE
5.8.4.3 South Africa
TABLE 5 REGULATORY AGENCIES AND GUIDELINES
5.9 TIMELINE FOR THERANOSTICS MARKET
5.10 REIMBURSEMENT ANALYSIS
TABLE 6 MEDICAL REIMBURSEMENT CODES FOR THERANOSTICS IN US, 2022
5.11 TRADE ANALYSIS
5.11.1 TRADE ANALYSIS FOR THERANOSTICS MARKET
TABLE 7 IMPORT DATA FOR RADIOPHARMACEUTICALS, BY COUNTRY, 2018–2022 (USD THOUSAND)
TABLE 8 EXPORT DATA FOR RADIOPHARMACEUTICALS, BY COUNTRY, 2018–2022 (USD THOUSAND)
5.12 PATENT ANALYSIS
FIGURE 23 TOP 10 PATENT APPLICANTS FOR THERANOSTICS (JANUARY 2012–DECEMBER 2022)
5.13 CASE STUDY ANALYSIS
TABLE 9 CASE STUDY 1: LUTETIUM-177-PSMA-617 FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
5.14 KEY STAKEHOLDERS & BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS
TABLE 10 KEY STAKEHOLDERS AND THEIR REQUIREMENTS
5.14.2 IMPACT ANALYSIS OF KEY BUYING CRITERIA
TABLE 11 IMPACT OF KEY STAKEHOLDERS ON BUYING CRITERIA
5.15 KEY CONFERENCES & EVENTS
TABLE 12 LIST OF KEY CONFERENCES & EVENTS, 2023–2024
5.16 CLINICAL RESEARCH DATA FOR THERANOSTICS MARKET
6 THERANOSTICS MARKET, BY PRODUCT
6.1 INTRODUCTION
TABLE 13 THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
6.2 DIAGNOSTIC IMAGING
6.2.1 EASY ANALYSIS OF DISEASE CONDITIONS AND ACCURATE THERAPIES TO DRIVE MARKET
TABLE 14 THERANOSTICS MARKET FOR DIAGNOSTIC IMAGING, BY REGION, 2021–2028 (USD MILLION)
6.3 RADIOPHARMACEUTICALS
TABLE 15 THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 16 THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY REGION, 2021–2028 (USD MILLION)
6.3.1 LUTETIUM-177
6.3.1.1 Increasing incidence of neuroendocrine cancer to boost segment
TABLE 17 LUTETIUM-177 MARKET, BY REGION, 2021–2028 (USD MILLION)
6.3.1.2 Samarium-153
6.3.1.3 Rising incidence of bone metastasis to drive segment growth
TABLE 18 SAMARIUM-153 MARKET, BY REGION, 2021–2028 (USD MILLION)
6.3.1.4 Radium-223
6.3.1.4.1 Easy production of Radium-223 molecule to support market growth
TABLE 19 RADIUM-223 MARKET, BY REGION, 2021–2028 (USD MILLION)
6.3.1.5 Iodine-131
6.3.1.5.1 Increased applications in thyroid cancer and hyperthyroidism treatment to propel market
TABLE 20 IODINE-131 MARKET, BY REGION, 2021–2028 (USD MILLION)
6.3.1.6 Yttrium-90
6.3.1.6.1 Rising use in non-Hodgkin lymphoma and oncology radiotheranostics to drive segment
TABLE 21 YTTRIUM-90 MARKET, BY REGION, 2021–2028 (USD MILLION)
6.3.1.7 Other radiopharmaceuticals
TABLE 22 OTHER RADIOPHARMACEUTICALS MARKET, BY REGION, 2021–2028 (USD MILLION)
6.4 IVD/BIOMARKER SCREENING
6.4.1 RISING ADOPTION OF THERANOSTICS TREATMENT TO SUPPORT MARKET GROWTH
TABLE 23 THERANOSTICS MARKET FOR IVD/BIOMARKER SCREENING, BY REGION, 2021–2028 (USD MILLION)
6.5 SOFTWARE & SERVICES
6.5.1 RISING USE OF NOVEL SOFTWARE AND INCREASING DEMAND FOR IMAGING SERVICES TO PROPEL MARKET
TABLE 24 THERANOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2021–2028 (USD MILLION)
7 THERANOSTICS MARKET, BY APPLICATION
7.1 INTRODUCTION
TABLE 25 THERANOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
7.2 PROSTATE CANCER
7.2.1 RISING INCIDENCE OF PROSTATE CANCER AMONG MEN TO FUEL MARKET
TABLE 26 THERANOSTICS MARKET FOR PROSTATE CANCER, BY REGION, 2021–2028 (USD MILLION)
7.3 BONE METASTASIS
7.3.1 INTRODUCTION OF NOVEL MEDICAL THERAPIES TO DRIVE MARKET
TABLE 27 THERANOSTICS MARKET FOR BONE METASTASIS, BY REGION, 2021–2028 (USD MILLION)
7.4 OTHER CANCERS
TABLE 28 THERANOSTICS MARKET FOR OTHER CANCERS, BY REGION, 2021–2028 (USD MILLION)
7.5 OTHER APPLICATIONS
TABLE 29 THERANOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
8 THERANOSTICS MARKET, BY END USER
8.1 INTRODUCTION
TABLE 30 THERANOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
8.2 HOSPITALS AND CANCER CARE CENTERS
8.2.1 RISING TREND OF MODERNIZING IMAGING WORKFLOW SYSTEMS TO DRIVE MARKET
TABLE 31 THERANOSTICS MARKET FOR HOSPITALS AND CANCER CARE CENTERS, BY REGION, 2021–2028 (USD MILLION)
8.3 THERANOSTICS CENTERS
8.3.1 GROWING FOCUS ON TARGETED THERAPIES AND RISING PREVALENCE OF CHRONIC DISEASES TO PROPEL MARKET
TABLE 32 THERANOSTICS MARKET FOR THERANOSTICS CENTERS, BY REGION, 2021–2028 (USD MILLION)
8.4 RESEARCH AND ACADEMIC CENTERS
8.4.1 INCREASING COLLABORATIONS BETWEEN THERANOSTICS COMPANIES AND ACADEMIA TO SUPPORT MARKET GROWTH
TABLE 33 THERANOSTICS MARKET FOR RESEARCH AND ACADEMIC CENTERS, BY REGION, 2021–2028 (USD MILLION)
9 THERANOSTICS MARKET, BY REGION
9.1 INTRODUCTION
TABLE 34 THERANOSTICS MARKET, BY REGION, 2021–2028 (USD MILLION)
9.2 NORTH AMERICA
FIGURE 24 NORTH AMERICA: CANCER PREVALENCE, 2012–2020
FIGURE 25 NORTH AMERICA: THERANOSTICS MARKET SNAPSHOT (2022)
TABLE 35 NORTH AMERICA: THERANOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 36 NORTH AMERICA: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 37 NORTH AMERICA: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 38 NORTH AMERICA: THERANOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 39 NORTH AMERICA: THERANOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
9.3 NORTH AMERICA: RECESSION IMPACT
9.3.1 US
9.3.1.1 US to dominate North American theranostics market during forecast period
TABLE 40 US: KEY MACROINDICATORS
TABLE 41 US: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 42 US: THERANOSTICS MARKET RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
9.3.2 CANADA
9.3.2.1 Rising geriatric population and increasing number of initiatives for medical isotope development to drive market
TABLE 43 CANADA: KEY MACROINDICATORS
TABLE 44 CANADA: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 45 CANADA: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
9.4 EUROPE
TABLE 46 EUROPE: THERANOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 47 EUROPE: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 48 EUROPE: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 49 EUROPE: THERANOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 50 EUROPE: THERANOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
9.4.1 EUROPE: RECESSION IMPACT
9.4.2 GERMANY
9.4.2.1 Well-established healthcare system and increased geriatric population to drive market
TABLE 51 GERMANY: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 52 GERMANY: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
9.4.3 UK
9.4.3.1 Increasing government funding in diagnostic imaging to support market growth
TABLE 53 UK: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 54 UK: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
9.4.4 FRANCE
9.4.4.1 Favorable government initiatives and high incidence of cancer to propel market
TABLE 55 FRANCE: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 56 FRANCE: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
9.4.5 REST OF EUROPE
TABLE 57 REST OF EUROPE: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 58 REST OF EUROPE: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
9.5 ASIA PACIFIC
FIGURE 26 ASIA PACIFIC: CANCER PREVALENCE, 2012–2020
FIGURE 27 ASIA PACIFIC: THERANOSTICS MARKET SNAPSHOT (2022)
TABLE 59 ASIA PACIFIC: THERANOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 60 ASIA PACIFIC: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 61 ASIA PACIFIC: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 62 ASIA PACIFIC: THERANOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 63 ASIA PACIFIC: THERANOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
9.5.1 ASIA PACIFIC: RECESSION IMPACT
9.5.2 JAPAN
9.5.2.1 Established nuclear medicine infrastructure and better accessibility of healthcare services to drive market
TABLE 64 JAPAN: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 65 JAPAN: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
9.5.3 CHINA
9.5.3.1 Increasing number of government initiatives and growing geriatric population to drive market
TABLE 66 CHINA: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 67 CHINA: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
9.5.4 INDIA
9.5.4.1 Rising number of nuclear medicine facilities and increasing incidence of chronic diseases to propel market
TABLE 68 INDIA: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 69 INDIA: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
9.5.5 REST OF ASIA PACIFIC
TABLE 70 REST OF ASIA PACIFIC: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 71 REST OF ASIA PACIFIC: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
9.6 REST OF THE WORLD
TABLE 72 REST OF THE WORLD: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 73 REST OF THE WORLD: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 74 REST OF THE WORLD: THERANOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 75 REST OF THE WORLD: THERANOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
9.6.1 REST OF THE WORLD: RECESSION IMPACT
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 KEY STRATEGIES/RIGHT TO WIN
10.3 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN THERANOSTICS MARKET
FIGURE 28 KEY STRATEGIES ADOPTED BY MAJOR PLAYERS IN THERANOSTICS MARKET
10.4 REVENUE SHARE ANALYSIS
FIGURE 29 REVENUE SHARE ANALYSIS OF TOP THREE PLAYERS, 2020–2022
10.5 MARKET SHARE ANALYSIS
FIGURE 30 ADVANCED ACCELERATOR APPLICATIONS COMMANDED LARGEST MARKET SHARE IN 2022
TABLE 76 DEGREE OF COMPETITION IN THERANOSTICS MARKET
10.6 COMPANY EVALUATION MATRIX
10.6.1 STARS
10.6.2 EMERGING LEADERS
10.6.3 PERVASIVE PLAYERS
10.6.4 PARTICIPANTS
FIGURE 31 COMPANY EVALUATION MATRIX, 2022
10.6.5 COMPANY FOOTPRINT
TABLE 77 PRODUCT AND REGIONAL FOOTPRINT
10.7 START-UP/SME EVALUATION MATRIX
10.7.1 PROGRESSIVE COMPANIES
10.7.2 RESPONSIVE COMPANIES
10.7.3 DYNAMIC COMPANIES
10.7.4 STARTING BLOCKS
FIGURE 32 START-UP/SME EVALUATION MATRIX, 2022
10.7.5 COMPETITIVE BENCHMARKING
TABLE 78 DETAILED LIST OF KEY START-UPS/SMES
10.8 COMPETITIVE SCENARIOS & TRENDS
11 COMPANY PROFILES
11.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
11.1.1 ADVANCED ACCELERATOR APPLICATIONS
TABLE 81 ADVANCED ACCELERATOR APPLICATIONS: COMPANY OVERVIEW
11.1.2 BAYER AG
TABLE 82 BAYER AG: COMPANY OVERVIEW
FIGURE 33 BAYER AG: COMPANY SNAPSHOT (2022)
11.1.3 GE HEALTHCARE
TABLE 83 GE HEALTHCARE: COMPANY OVERVIEW
FIGURE 34 GE HEALTHCARE: COMPANY SNAPSHOT (2022)
11.1.4 SIEMENS HEALTHINEERS AG
TABLE 84 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
FIGURE 35 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022)
11.1.5 CARDINAL HEALTH
TABLE 85 CARDINAL HEALTH: COMPANY OVERVIEW
FIGURE 36 CARDINAL HEALTH: COMPANY SNAPSHOT (2022)
11.1.6 PHILIPS HEALTHCARE
TABLE 86 PHILIPS HEALTHCARE: COMPANY OVERVIEW
FIGURE 37 PHILIPS HEALTHCARE: COMPANY SNAPSHOT (2022)
11.1.7 CANON INC.
TABLE 87 CANON INC.: COMPANY OVERVIEW
FIGURE 38 CANON INC.: COMPANY SNAPSHOT (2022)
11.1.8 CURIUM
TABLE 88 CURIUM: COMPANY OVERVIEW
11.1.9 LANTHEUS
TABLE 89 LANTHEUS: COMPANY OVERVIEW
FIGURE 39 LANTHEUS: COMPANY SNAPSHOT (2022)
11.1.10 NORTHSTAR MEDICAL RADIOISOTOPES
TABLE 90 NORTHSTAR MEDICAL RADIOISOTOPES: COMPANY OVERVIEW
11.1.11 ECKERT & ZIEGLER
TABLE 91 ECKERT & ZIEGLER: COMPANY OVERVIEW
FIGURE 40 ECKERT & ZIEGLER: COMPANY SNAPSHOT (2022)
11.1.12 PHARMALOGIC
TABLE 92 PHARMALOGIC: COMPANY OVERVIEW
11.1.13 ECZACIBAЄI-MONROL
TABLE 93 ECZACIBAЄI-MONROL: COMPANY OVERVIEW
11.1.14 ACROTECH BIOPHARMA, INC.
TABLE 94 ACROTECH BIOPHARMA, INC.: COMPANY OVERVIEW
11.2 OTHER PLAYERS
11.2.1 THERMO FISHER SCIENTIFIC INC.
11.2.2 GLOBAL MEDICAL SOLUTIONS
11.2.3 SHINE TECHNOLOGIES, LLC
11.2.4 ISOTOPIA MOLECULAR IMAGING LTD.
11.2.5 INSTITUTE OF ISOTOPES
11.2.6 CHINA ISOTOPE & RADIATION CORPORATION
11.2.7 YANTAI DONGCHENG PHARMACEUTICAL GROUP CO., LTD.
11.2.8 ATOMVIE
11.2.9 ABX ADVANCED BIOCHEMICAL COMPOUNDS GMBH
11.2.10 TELIX PHARMACEUTICALS LIMITED
11.2.11 BLUE EARTH DIAGNOSTICS
11.2.12 SOFIE BIOSCIENCES
11.2.13 THERAGNOSTICS
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
12 APPENDIX
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 CUSTOMIZATION OPTIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 INCLUSIONS & EXCLUSIONS
1.4 MARKET SEGMENTATION
1.4.1 MARKETS COVERED
1.4.2 REGIONS COVERED
1.4.3 YEARS CONSIDERED
1.4.4 CURRENCY CONSIDERED
1.5 RESEARCH LIMITATIONS
1.6 STAKEHOLDERS
1.7 RECESSION IMPACT: THERANOSTICS MARKET
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN METHODOLOGY
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.1.2.1 Primary sources
2.1.2.2 Key industry insights
2.1.2.3 Breakdown of primaries
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 Approach 1: Company revenue estimation approach
FIGURE 5 COMPANY REVENUE ESTIMATION
FIGURE 6 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF BAYER AG
2.2.1.2 Approach 2: Patient population-based market estimation
FIGURE 7 BOTTOM-UP APPROACH: THERANOSTICS MARKET
2.2.1.3 Growth forecast
2.2.1.4 CAGR projections
FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 9 DATA TRIANGULATION METHODOLOGY
2.3.1 MARKET SHARE ESTIMATION
2.4 STUDY ASSUMPTIONS
2.4.1 MARKET ASSUMPTIONS
2.4.2 GROWTH RATE ASSUMPTIONS
2.5 RISK ASSESSMENT
TABLE 1 RISK ASSESSMENT: THERANOSTICS MARKET
2.6 IMPACT OF ECONOMIC RECESSION ON THERANOSTICS MARKET
3 EXECUTIVE SUMMARY
FIGURE 10 THERANOSTICS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
FIGURE 11 THERANOSTICS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
FIGURE 12 THERANOSTICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 13 REGIONAL SNAPSHOT OF THERANOSTICS MARKET
4 PREMIUM INSIGHTS
4.1 THERANOSTICS MARKET OVERVIEW
FIGURE 14 RISING PREVALENCE OF CANCER AND GROWING FOCUS ON PRECISION MEDICINE TO DRIVE MARKET
4.2 NORTH AMERICA: THERANOSTICS MARKET, BY PRODUCT (USD MILLION)
FIGURE 15 RADIOPHARMACEUTICALS TO COMMAND LARGEST MARKET SHARE IN NORTH AMERICAN THERANOSTICS MARKET DURING FORECAST PERIOD
4.3 EUROPE: THERANOSTICS MARKET, BY APPLICATION (USD MILLION)
FIGURE 16 PROSTATE CANCER TO REGISTER HIGHEST GROWTH RATE DURING STUDY PERIOD
4.4 ASIA PACIFIC: THERANOSTICS MARKET, BY END USER (USD MILLION)
FIGURE 17 HOSPITALS AND CANCER CARE CENTERS TO COMMAND LARGEST SHARE IN ASIA PACIFIC MARKET DURING FORECAST PERIOD
4.5 GEOGRAPHIC SNAPSHOT: THERANOSTICS MARKET
FIGURE 18 CHINA TO WITNESS HIGHEST GROWTH RATE DURING STUDY PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 19 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: THERANOSTICS MARKET
5.2.1 DRIVERS
5.2.1.1 Growing geriatric population and rising prevalence of target diseases
5.2.1.2 Increasing use of radiopharmaceuticals in neurological applications
5.2.1.3 Growing focus on precision medicine
5.2.2 RESTRAINTS
5.2.2.1 Short half-life of radiopharmaceuticals
TABLE 2 PHYSICAL HALF-LIFE OF RADIOPHARMACEUTICALS
5.2.2.2 Unfavorable healthcare reimbursement scenario
5.2.3 OPPORTUNITIES
5.2.3.1 Growth opportunities in emerging economies
5.2.3.2 Rising number of R&D programs for radiopharmaceuticals
5.2.4 CHALLENGES
5.2.4.1 Hospital budget cuts and high equipment costs
5.3 PRICING ANALYSIS
FIGURE 20 AVERAGE SELLING PRICE FOR RADIOPHARMACEUTICALS
TABLE 3 AVERAGE COST FOR THERANOSTICS TREATMENT, BY REGION
5.4 VALUE CHAIN ANALYSIS
FIGURE 21 VALUE CHAIN ANALYSIS: THERANOSTICS MARKET
5.5 ECOSYSTEM/MARKET MAP
5.6 SUPPLY CHAIN ANALYSIS
5.6.1 PROMINENT COMPANIES
5.6.2 SMALL & MEDIUM-SIZED ENTERPRISES
5.6.3 END USERS
FIGURE 22 SUPPLY CHAIN ANALYSIS: THERANOSTICS MARKET
5.7 PORTER’S FIVE FORCES ANALYSIS
TABLE 4 PORTER’S FIVE FORCES ANALYSIS: THERANOSTICS MARKET
5.7.1 INTENSITY OF COMPETITIVE RIVALRY
5.7.2 BARGAINING POWER OF SUPPLIERS
5.7.3 BARGAINING POWER OF BUYERS
5.7.4 THREAT OF SUBSTITUTES
5.7.5 THREAT OF NEW ENTRANTS
5.8 REGULATORY LANDSCAPE
5.8.1 NORTH AMERICA
5.8.1.1 US
5.8.1.2 Canada
5.8.2 EUROPE
5.8.3 ASIA PACIFIC
5.8.3.1 Australia
5.8.3.2 India
5.8.3.3 China
5.8.4 REST OF THE WORLD
5.8.4.1 Turkey
5.8.4.2 UAE
5.8.4.3 South Africa
TABLE 5 REGULATORY AGENCIES AND GUIDELINES
5.9 TIMELINE FOR THERANOSTICS MARKET
5.10 REIMBURSEMENT ANALYSIS
TABLE 6 MEDICAL REIMBURSEMENT CODES FOR THERANOSTICS IN US, 2022
5.11 TRADE ANALYSIS
5.11.1 TRADE ANALYSIS FOR THERANOSTICS MARKET
TABLE 7 IMPORT DATA FOR RADIOPHARMACEUTICALS, BY COUNTRY, 2018–2022 (USD THOUSAND)
TABLE 8 EXPORT DATA FOR RADIOPHARMACEUTICALS, BY COUNTRY, 2018–2022 (USD THOUSAND)
5.12 PATENT ANALYSIS
FIGURE 23 TOP 10 PATENT APPLICANTS FOR THERANOSTICS (JANUARY 2012–DECEMBER 2022)
5.13 CASE STUDY ANALYSIS
TABLE 9 CASE STUDY 1: LUTETIUM-177-PSMA-617 FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
5.14 KEY STAKEHOLDERS & BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS
TABLE 10 KEY STAKEHOLDERS AND THEIR REQUIREMENTS
5.14.2 IMPACT ANALYSIS OF KEY BUYING CRITERIA
TABLE 11 IMPACT OF KEY STAKEHOLDERS ON BUYING CRITERIA
5.15 KEY CONFERENCES & EVENTS
TABLE 12 LIST OF KEY CONFERENCES & EVENTS, 2023–2024
5.16 CLINICAL RESEARCH DATA FOR THERANOSTICS MARKET
6 THERANOSTICS MARKET, BY PRODUCT
6.1 INTRODUCTION
TABLE 13 THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
6.2 DIAGNOSTIC IMAGING
6.2.1 EASY ANALYSIS OF DISEASE CONDITIONS AND ACCURATE THERAPIES TO DRIVE MARKET
TABLE 14 THERANOSTICS MARKET FOR DIAGNOSTIC IMAGING, BY REGION, 2021–2028 (USD MILLION)
6.3 RADIOPHARMACEUTICALS
TABLE 15 THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 16 THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY REGION, 2021–2028 (USD MILLION)
6.3.1 LUTETIUM-177
6.3.1.1 Increasing incidence of neuroendocrine cancer to boost segment
TABLE 17 LUTETIUM-177 MARKET, BY REGION, 2021–2028 (USD MILLION)
6.3.1.2 Samarium-153
6.3.1.3 Rising incidence of bone metastasis to drive segment growth
TABLE 18 SAMARIUM-153 MARKET, BY REGION, 2021–2028 (USD MILLION)
6.3.1.4 Radium-223
6.3.1.4.1 Easy production of Radium-223 molecule to support market growth
TABLE 19 RADIUM-223 MARKET, BY REGION, 2021–2028 (USD MILLION)
6.3.1.5 Iodine-131
6.3.1.5.1 Increased applications in thyroid cancer and hyperthyroidism treatment to propel market
TABLE 20 IODINE-131 MARKET, BY REGION, 2021–2028 (USD MILLION)
6.3.1.6 Yttrium-90
6.3.1.6.1 Rising use in non-Hodgkin lymphoma and oncology radiotheranostics to drive segment
TABLE 21 YTTRIUM-90 MARKET, BY REGION, 2021–2028 (USD MILLION)
6.3.1.7 Other radiopharmaceuticals
TABLE 22 OTHER RADIOPHARMACEUTICALS MARKET, BY REGION, 2021–2028 (USD MILLION)
6.4 IVD/BIOMARKER SCREENING
6.4.1 RISING ADOPTION OF THERANOSTICS TREATMENT TO SUPPORT MARKET GROWTH
TABLE 23 THERANOSTICS MARKET FOR IVD/BIOMARKER SCREENING, BY REGION, 2021–2028 (USD MILLION)
6.5 SOFTWARE & SERVICES
6.5.1 RISING USE OF NOVEL SOFTWARE AND INCREASING DEMAND FOR IMAGING SERVICES TO PROPEL MARKET
TABLE 24 THERANOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2021–2028 (USD MILLION)
7 THERANOSTICS MARKET, BY APPLICATION
7.1 INTRODUCTION
TABLE 25 THERANOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
7.2 PROSTATE CANCER
7.2.1 RISING INCIDENCE OF PROSTATE CANCER AMONG MEN TO FUEL MARKET
TABLE 26 THERANOSTICS MARKET FOR PROSTATE CANCER, BY REGION, 2021–2028 (USD MILLION)
7.3 BONE METASTASIS
7.3.1 INTRODUCTION OF NOVEL MEDICAL THERAPIES TO DRIVE MARKET
TABLE 27 THERANOSTICS MARKET FOR BONE METASTASIS, BY REGION, 2021–2028 (USD MILLION)
7.4 OTHER CANCERS
TABLE 28 THERANOSTICS MARKET FOR OTHER CANCERS, BY REGION, 2021–2028 (USD MILLION)
7.5 OTHER APPLICATIONS
TABLE 29 THERANOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
8 THERANOSTICS MARKET, BY END USER
8.1 INTRODUCTION
TABLE 30 THERANOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
8.2 HOSPITALS AND CANCER CARE CENTERS
8.2.1 RISING TREND OF MODERNIZING IMAGING WORKFLOW SYSTEMS TO DRIVE MARKET
TABLE 31 THERANOSTICS MARKET FOR HOSPITALS AND CANCER CARE CENTERS, BY REGION, 2021–2028 (USD MILLION)
8.3 THERANOSTICS CENTERS
8.3.1 GROWING FOCUS ON TARGETED THERAPIES AND RISING PREVALENCE OF CHRONIC DISEASES TO PROPEL MARKET
TABLE 32 THERANOSTICS MARKET FOR THERANOSTICS CENTERS, BY REGION, 2021–2028 (USD MILLION)
8.4 RESEARCH AND ACADEMIC CENTERS
8.4.1 INCREASING COLLABORATIONS BETWEEN THERANOSTICS COMPANIES AND ACADEMIA TO SUPPORT MARKET GROWTH
TABLE 33 THERANOSTICS MARKET FOR RESEARCH AND ACADEMIC CENTERS, BY REGION, 2021–2028 (USD MILLION)
9 THERANOSTICS MARKET, BY REGION
9.1 INTRODUCTION
TABLE 34 THERANOSTICS MARKET, BY REGION, 2021–2028 (USD MILLION)
9.2 NORTH AMERICA
FIGURE 24 NORTH AMERICA: CANCER PREVALENCE, 2012–2020
FIGURE 25 NORTH AMERICA: THERANOSTICS MARKET SNAPSHOT (2022)
TABLE 35 NORTH AMERICA: THERANOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 36 NORTH AMERICA: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 37 NORTH AMERICA: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 38 NORTH AMERICA: THERANOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 39 NORTH AMERICA: THERANOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
9.3 NORTH AMERICA: RECESSION IMPACT
9.3.1 US
9.3.1.1 US to dominate North American theranostics market during forecast period
TABLE 40 US: KEY MACROINDICATORS
TABLE 41 US: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 42 US: THERANOSTICS MARKET RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
9.3.2 CANADA
9.3.2.1 Rising geriatric population and increasing number of initiatives for medical isotope development to drive market
TABLE 43 CANADA: KEY MACROINDICATORS
TABLE 44 CANADA: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 45 CANADA: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
9.4 EUROPE
TABLE 46 EUROPE: THERANOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 47 EUROPE: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 48 EUROPE: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 49 EUROPE: THERANOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 50 EUROPE: THERANOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
9.4.1 EUROPE: RECESSION IMPACT
9.4.2 GERMANY
9.4.2.1 Well-established healthcare system and increased geriatric population to drive market
TABLE 51 GERMANY: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 52 GERMANY: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
9.4.3 UK
9.4.3.1 Increasing government funding in diagnostic imaging to support market growth
TABLE 53 UK: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 54 UK: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
9.4.4 FRANCE
9.4.4.1 Favorable government initiatives and high incidence of cancer to propel market
TABLE 55 FRANCE: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 56 FRANCE: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
9.4.5 REST OF EUROPE
TABLE 57 REST OF EUROPE: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 58 REST OF EUROPE: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
9.5 ASIA PACIFIC
FIGURE 26 ASIA PACIFIC: CANCER PREVALENCE, 2012–2020
FIGURE 27 ASIA PACIFIC: THERANOSTICS MARKET SNAPSHOT (2022)
TABLE 59 ASIA PACIFIC: THERANOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 60 ASIA PACIFIC: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 61 ASIA PACIFIC: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 62 ASIA PACIFIC: THERANOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 63 ASIA PACIFIC: THERANOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
9.5.1 ASIA PACIFIC: RECESSION IMPACT
9.5.2 JAPAN
9.5.2.1 Established nuclear medicine infrastructure and better accessibility of healthcare services to drive market
TABLE 64 JAPAN: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 65 JAPAN: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
9.5.3 CHINA
9.5.3.1 Increasing number of government initiatives and growing geriatric population to drive market
TABLE 66 CHINA: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 67 CHINA: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
9.5.4 INDIA
9.5.4.1 Rising number of nuclear medicine facilities and increasing incidence of chronic diseases to propel market
TABLE 68 INDIA: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 69 INDIA: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
9.5.5 REST OF ASIA PACIFIC
TABLE 70 REST OF ASIA PACIFIC: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 71 REST OF ASIA PACIFIC: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
9.6 REST OF THE WORLD
TABLE 72 REST OF THE WORLD: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 73 REST OF THE WORLD: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 74 REST OF THE WORLD: THERANOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 75 REST OF THE WORLD: THERANOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
9.6.1 REST OF THE WORLD: RECESSION IMPACT
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 KEY STRATEGIES/RIGHT TO WIN
10.3 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN THERANOSTICS MARKET
FIGURE 28 KEY STRATEGIES ADOPTED BY MAJOR PLAYERS IN THERANOSTICS MARKET
10.4 REVENUE SHARE ANALYSIS
FIGURE 29 REVENUE SHARE ANALYSIS OF TOP THREE PLAYERS, 2020–2022
10.5 MARKET SHARE ANALYSIS
FIGURE 30 ADVANCED ACCELERATOR APPLICATIONS COMMANDED LARGEST MARKET SHARE IN 2022
TABLE 76 DEGREE OF COMPETITION IN THERANOSTICS MARKET
10.6 COMPANY EVALUATION MATRIX
10.6.1 STARS
10.6.2 EMERGING LEADERS
10.6.3 PERVASIVE PLAYERS
10.6.4 PARTICIPANTS
FIGURE 31 COMPANY EVALUATION MATRIX, 2022
10.6.5 COMPANY FOOTPRINT
TABLE 77 PRODUCT AND REGIONAL FOOTPRINT
10.7 START-UP/SME EVALUATION MATRIX
10.7.1 PROGRESSIVE COMPANIES
10.7.2 RESPONSIVE COMPANIES
10.7.3 DYNAMIC COMPANIES
10.7.4 STARTING BLOCKS
FIGURE 32 START-UP/SME EVALUATION MATRIX, 2022
10.7.5 COMPETITIVE BENCHMARKING
TABLE 78 DETAILED LIST OF KEY START-UPS/SMES
10.8 COMPETITIVE SCENARIOS & TRENDS
11 COMPANY PROFILES
11.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
11.1.1 ADVANCED ACCELERATOR APPLICATIONS
TABLE 81 ADVANCED ACCELERATOR APPLICATIONS: COMPANY OVERVIEW
11.1.2 BAYER AG
TABLE 82 BAYER AG: COMPANY OVERVIEW
FIGURE 33 BAYER AG: COMPANY SNAPSHOT (2022)
11.1.3 GE HEALTHCARE
TABLE 83 GE HEALTHCARE: COMPANY OVERVIEW
FIGURE 34 GE HEALTHCARE: COMPANY SNAPSHOT (2022)
11.1.4 SIEMENS HEALTHINEERS AG
TABLE 84 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
FIGURE 35 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022)
11.1.5 CARDINAL HEALTH
TABLE 85 CARDINAL HEALTH: COMPANY OVERVIEW
FIGURE 36 CARDINAL HEALTH: COMPANY SNAPSHOT (2022)
11.1.6 PHILIPS HEALTHCARE
TABLE 86 PHILIPS HEALTHCARE: COMPANY OVERVIEW
FIGURE 37 PHILIPS HEALTHCARE: COMPANY SNAPSHOT (2022)
11.1.7 CANON INC.
TABLE 87 CANON INC.: COMPANY OVERVIEW
FIGURE 38 CANON INC.: COMPANY SNAPSHOT (2022)
11.1.8 CURIUM
TABLE 88 CURIUM: COMPANY OVERVIEW
11.1.9 LANTHEUS
TABLE 89 LANTHEUS: COMPANY OVERVIEW
FIGURE 39 LANTHEUS: COMPANY SNAPSHOT (2022)
11.1.10 NORTHSTAR MEDICAL RADIOISOTOPES
TABLE 90 NORTHSTAR MEDICAL RADIOISOTOPES: COMPANY OVERVIEW
11.1.11 ECKERT & ZIEGLER
TABLE 91 ECKERT & ZIEGLER: COMPANY OVERVIEW
FIGURE 40 ECKERT & ZIEGLER: COMPANY SNAPSHOT (2022)
11.1.12 PHARMALOGIC
TABLE 92 PHARMALOGIC: COMPANY OVERVIEW
11.1.13 ECZACIBAЄI-MONROL
TABLE 93 ECZACIBAЄI-MONROL: COMPANY OVERVIEW
11.1.14 ACROTECH BIOPHARMA, INC.
TABLE 94 ACROTECH BIOPHARMA, INC.: COMPANY OVERVIEW
11.2 OTHER PLAYERS
11.2.1 THERMO FISHER SCIENTIFIC INC.
11.2.2 GLOBAL MEDICAL SOLUTIONS
11.2.3 SHINE TECHNOLOGIES, LLC
11.2.4 ISOTOPIA MOLECULAR IMAGING LTD.
11.2.5 INSTITUTE OF ISOTOPES
11.2.6 CHINA ISOTOPE & RADIATION CORPORATION
11.2.7 YANTAI DONGCHENG PHARMACEUTICAL GROUP CO., LTD.
11.2.8 ATOMVIE
11.2.9 ABX ADVANCED BIOCHEMICAL COMPOUNDS GMBH
11.2.10 TELIX PHARMACEUTICALS LIMITED
11.2.11 BLUE EARTH DIAGNOSTICS
11.2.12 SOFIE BIOSCIENCES
11.2.13 THERAGNOSTICS
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
12 APPENDIX
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 CUSTOMIZATION OPTIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
